Skip to main content

Table 6 Distribution of RS overall and for different subgroups

From: Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Variable

RS median (range)

 All patients, N = 222

16 (0–68)

Tumor grade (BRE)

 G1, N = 28

14 (6–28)

 G2, N = 146

15 (0–51)

 G3, N = 48

24 (5–68)

pN stage

 pN0, N = 136

17 (0–68)

 pN1a, N = 86

14 (0–51)

Peritumoral lympho-vascular invasion

 No, N = 172

16 (0–68)

 Yes, N = 50

15 (2–44)

Invasive tumor size

  ≤ 2 cm, N = 133

15 (0–43)

  > 2 cm, N = 89

16 (0–68)

Ki67

  ≤ 30, N = 193

15 (0–51)

  > 30, N = 29

24 (1–68)